Furthermore, while a trend towards benefit was noted in BRCA1-mutant cases, no significant improvement was observed in BRCA2-mutant or HRD-positive tumours, suggesting that, in HGSOC, immunological consequences of genomic instability must be interpreted within a broader, integrated immunological and genomic context to accurately predict benefit from ICB. This evidence concerns the gene BRCA1 and neoplasm.